AnaptysBio Q2 FY26 net income from continuing operations more than doubles to $177.3 million; revenue rises 23.5% to $27.49 million

Bitget2026/09/21 20:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AnaptysBio posted Q2 net income from continuing operations of USD 177.3 million, versus USD 5.7 million a year earlier.
Q2 collaboration revenue rose 23.47% year over year to USD 27.49 million, while general and administrative expenses climbed to USD 16.04 million.
Cash, cash equivalents and investments totaled USD 164.1 million at June 30, down from USD 211.6 million at Dec. 31, 2025.
Management flagged Jemperli global net sales of USD 644 million for the six months ended June 30, up 34% year over year.
Updates include a Feb. 2027 FDA PDUFA date for Jemperli in rectal cancer and a Dec. 12, 2026 PDUFA date for Quimilza in GPP.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609211615PRIMZONEFULLFEED9830768) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AnaptysBio Q2 FY26 net income from continuing operations more than doubles to $177.3 million; revenue rises 23.5% to $27.49 million

You may also like

Crypto prices